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In order to understand the biological and molecular mechanisms underlying 
disease resistance to therapy in pediatric acute lymphoblastic leukemia (ALL), we 
performed an investigation utilizing single-cell RNA-sequencing (scRNA-seq) on the 
10X Genomics Chromium platform. Bone marrow samples from seven patients were 
collected, four of whom exhibited measurable residual disease (MRD) after induction 
therapy, and three patients who did not. Cells from bone marrow tissue were extracted 
from each patient at the time of diagnosis, prior to treatment efforts. Leukemic cells were 
separated from peripheral immune cells using flow cytometry and ~1000 single cells 
were sequenced from each patients’ cell populations. The goal of this study was to 
discern how the immune and leukemic cell populations and gene expression therein vary 
at the time of diagnosis between patients who do or do not respond to induction. Our 
results demonstrate a comparative increase in immune exhaustion signatures in the 
immune cells of MRD-positive patients, corroborating previous findings that implicate 
the role of exhaustion in resistant disease. We also show a discrepancy of cell cycle states 
in the leukemic cell compartment according to disease outcome, with an enrichment of 
blasts from MRD-negative patients exhibiting genetic signatures of S- and G2/M-phase. 
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Acute lymphoblastic leukemia (ALL) is the most common malignant disease 
diagnosed in children1. While the disease is associated with a high remission rate, the 
15% of patients who relapse face diminished survival rates compared to those that do not 
experience recurrent ALL2. Currently, the most widely used treatment utilized for 
pediatric ALL patients is chemotherapy, a three-step process that begins with a critical 
phase known as induction3. During induction therapy patients typically receive three 
drugs: two chemotherapy drugs, often vincristine and asparaginase, and a corticosteroid3. 
The goal of this initial four-week stage is to achieve an absence of leukemic cells in the 
bone marrow or attain remission status3. The presence of leukemia cells, or measurable 
residual disease (MRD), is assessed after induction therapy, as this measure is heavily 
indicative of eventual patient outcome2. The high instance of recurrent ALL in children 
and its associated lower survival likelihood makes insight into the mechanisms involved 
in relapse of great importance to oncologic researchers4. Understanding the biological 
processes underlying patients’ failure to achieve remission following induction therapy is 
crucial for the development of means to reduce the instance of relapsed ALL in children4. 
A recently developed technology known as single-cell RNA-sequencing (scRNA-
seq) enables mass-sequencing of mRNA transcripts from many single cells at once5. 
Statistical analysis of the abundance of each transcript in individual cells allows for 
determination of differential gene expression, which often provides insight into the 
biological processes taking place in each cell6. This is an incredible advance over bulk 
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tissue RNA sequencing since it allows discrimination of both the distribution of diverse 
cell types and their molecular differences among patients. 
Both bulk and single-cell RNA-sequencing methods have been previously 
employed to characterize the biological processes involved in ALL relapse. In an 
assessment of RNA expression in single leukemic cells in untreated controls and 
leukemic cells persisting in mice treated with two chemotherapy drugs, Ebinger et al 
(2016) found that the MRD cells had low expression of genes involved in cell cycle and 
DNA replication, but high expression of genes that facilitate cell adhesion7. However, the 
use of immunocompromised mouse models limits the direct application of these findings 
to human disease, and because only leukemic cells were analyzed, no insight into the 
possible ways in which other immune cells may influence disease status during 
therapeutic implementation could be gained7. 
Other studies have implicated the importance of expression patterns in peripheral 
immune cells within the bone marrow in indicating a patient’s likelihood to respond to 
therapy. Sade-Feldman et al (2018) found that the expression of TGF7 in CD8+ T cells 
may serve as a predictor of patients’ ability to respond to immune checkpoint therapy 
(ICT), as might signatures of T cell exhaustion8. The limited focus of T cells in the work 
though does not permit comprehensive insight into the therapy’s effect on all immune 
cells8. A scRNA-seq study of T-ALL patient bone marrow conducted by De Bie et al 
(2018) suggested that malignancy-inducing mutations tend to accumulate in multipotent 
progenitor cells, suggesting an unmet need for therapies that target these early cells9.  
Finally, Witkowski et al (2020) implicated the role of monocyte abundance in B-
ALL disease progression—namely, they found that diagnosis and relapse samples 
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exhibited increased abundance of non-classical monocytes, and further demonstrated that 
high abundance of monocytes may be used to predict patient survival10. Furthermore, 
they revealed that non-classical monocytes at diagnosis and relapse showed increased 
expression of genes involved in vascular endothelial interactions, namely PCAM1, 
TNFSF10, and CX3CR110. However, the initial separation of the bone marrow cells into 
CD19+ B cells and CD19-CD45+ non-B cells may have compromised the ability to infer 
how the leukemic cell population explicitly differs from the peripheral immune cells in 
the bone marrow10. Such information is valuable, as it could potentially unveil variation 
in both the cell profiles and the interactions between these populations of cells in patients 
who do or do not respond to induction therapy. 
In this pilot study, we aimed to provide additional information about the 
biological differences between patients who achieve remission and those who do not. 
Specifically, we focused on discerning discrepancies in the immune and leukemic cell 
profiles and gene expression therein between patients who have MRD after induction 
therapy and those that do not. This analysis was carried out via utilization of scRNA-seq 
on cells extracted and isolated from the bone marrow tissue of leukemia patients at the 
time of diagnosis. Flow cytometry was first done in order to separate the leukemic cells 
from the peripheral immune cell populations. mRNA transcripts were acquired from two 
samples associated with each patient: leukemia cells at diagnosis and immune cells at 
diagnosis. Statistical analyses were then performed on each patients’ scRNA-seq data in 
order to characterize the cells and assess whether they exhibit significant differential gene 
expression, specifically comparing patients with and without MRD after the completion 
of induction.  
 
8 
Considering the immunological patterns associated with ALL disease outcome in 
the previous studies, we developed a three-fold hypothesis. First, we anticipated 
divergent cell type frequencies and gene expression profiles between patients who did vs 
did not achieve remission. More specifically, we expected that MRD-positive patients 
would have signatures of immune cell exhaustion and dormant leukemic states, while 
patients who achieved remission would have a higher proportion of proliferating 
leukemic cells. This study aims to provide further insight into how immunity and 
malignancy differ between therapy-responsive versus unresponsive patients at the time of 
diagnosis, so that such information may be applied to future work in improving clinical 




Extraction and Sequencing 
Bone marrow samples from seven patients were collected, four of whom 
exhibited MRD after induction, and three patients who did not. Flow cytometry was used 
to separate CD45+CD10+CD19+ blasts from all other viable CD45+ cells to separate 
leukemic cells from peripheral immune cells. From each patient, scRNA was sequenced 
from ~1000 cells each from peripheral immune cells and leukemic cells before treatment. 
Patients’ DNA was also extracted and genotyped for post-sequencing annotation of cells 
by individual. 
Genotyping, QC and Cell Annotation 
In scRNAseq analysis, transcripts are assigned three barcodes, one for the sample, 
one for the cell, and one UMI (unique molecular identifier) for the actual mRNA 
molecule.  Since we pooled four individuals into one sample to save costs, a fourth 
barcode was required to assign cells to individuals.  This barcode is actually the 
genotypes ascertained from the RNA sequence reads, which are compared to each 
individual’s genotype profile with Demuxlet software11. Once labeled, the transcript data 
was processed using the Seurat package in R® statistical software. Quality control was 
implemented on the samples to retain cells only with transcripts for more than 200 unique 
genes and less than 30% mitochondrial contribution. The batched samples were then 
separated by individual.  
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All samples, both leukemic and nonleukemic, were then combined into one data 
object to ensure that flow cytometry had effectively separated malignant cells from 
peripheral immune cells. The combined data object was log-normalized and scaled using 
the most highly variable genes in the dataset. Principal component analysis (PCA) was 
performed and used in Shared Nearest Neighbor (SNN) analysis was implemented in 
Seurat’s FindNeighbors function, followed by a Uniform Manifold Approximation and 
Projection (UMAP) dimensional reduction technique, both using a dimensions parameter 
of 1:35. Finally, a UMAP plot was constructed and clusters were visually separated by 
malignancy. The groups of non-leukemic cells that mapped with the leukemic clusters 
were relabeled to reflect their true malignant identities. The few leukemic cells that 
mapped to the peripheral immune cell regions were omitted from downstream analyses.  
Cell Clustering and Characterization 
Once the cells were labeled to reflect their true malignancy states, analysis of non-
leukemic and leukemic cell populations were performed separately. The nonleukemic 
cells were analyzed first, beginning with splitting the data object according to individual. 
Each subject’s data was normalized and scaled using Seurat’s SCTransform function. 
Each individual’s sample was then combined back into a combined data object using 
Seurat’s integration workflow to account for possible batch effects in the dataset. PCA, 
SNN and UMAP were then run as had been done previously, again with dimensions 1:35. 
UMAP plots were constructed at various resolutions and the variation with the most 
stable cluster assignment was chosen for downstream analysis - in this case, a resolution 
of 9.0, which resulted in a total of 57 distinct cell clusters. After grouping these cells to 
these clusters, the original raw counts of the combined object were log-normalized and 
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scaled using the most highly variable genes. Cell-specific gene markers were assessed in 
each cluster through the creation of Dot Plots, which provided guidance to label the 
various cluster groups by cell type. After investigating the expression of cell- specific 
genes across the clusters, the 57 cell groups were reduced to 11 distinct cell types. 
The workflow used to process the peripheral immune cells was also utilized to 
analyze the leukemic cell population. However, a UMAP resolution of 0.6 was found to 
be most stable for these cells, resulting in 10 total leukemic clusters. The original count 
data for these cells were also log-normalized and scaled using the most highly variable 
genes, however this time Seurat’s FindMarkers function was utilized to determine the 
RNA transcripts positively defining each of the 10 cell groups. For each cluster, the genes 
with a p-adjusted (p-adj) less than 0.05 were input into functional enrichment analysis, 
ToppFun12.   
The CellCycleScoring pipeline was then run on the leukemic cells, which assigns 
each cell a score based on its expression of G2/M and S phase genes. The resulting 
assignments were then evaluated according to the composition of the cell cycle phases by 
disease outcome, timepoint, and leukemic cluster. 
An assessment of immune cell exhaustion (loss of effector and proliferation 
activity) was conducted on the peripheral immune cell populations. Two methods were 
used to assign each cell a score based on their expression of exhaustion-specific marker 
genes. The first exhaustion measure was calculated by totaling the normalized expression 
values for each of the exhaustion genes for each cell. The second measure resulted from 
the summed raw number of exhaustion gene transcripts per cell, normalized by the total 
transcripts per cell. In each case, the distribution of scores across all cells was assessed, 
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and cells having upper-outlier score values in the two distributions were noted and 
labeled as highly exhausted cells.   
Analysis of Differentially Expressed Genes 
The major aim of this study was to unveil potential biological differences in the 
bone marrow compartment of ALL patients according to their post-therapeutic outcome. 
To do this, analyses were conducted evaluating the genes differentially expressed 
according to patient outcome across the samples. Differential gene expression was 
assessed using a Wilcoxon Rank Sum test between cell groups. This analysis was 
performed on the overall leukemic cell group as well as overall within the nonleukemic 
immune cell compartment to evaluate expression differences between cells from patients 
who did and did not have MRD post-induction. In addition to evaluating expression 
discrepancies according to disease outcome within these large cell groups, the same gene 
expression examination was conducted within each of the subpopulations comprising 
these cellular compartments. More specifically, outcome associated DEGs were 
determined within each of the leukemic cell clusters and within each of the immune cell 
groups. Genes were considered significantly differentially expressed if they exhibited a p-
adj value less than 0.05 and a log2FC value greater than 1. Such significant genes were 
also input to ToppFun for functional enrichment analysis12. Pathways with more than 100 





After quality control assessments and division of single cells into their malignant 
and non-malignant states, a total of 18,974 single cells were retained for further analysis: 
5,906 nonleukemic immune cells and 13,068 leukemic cells.  
Leukemic Cell Population 
After clustering, the leukemic cells were assigned to 10 distinct clusters, labeled 
0-9 (Fig. 1). Each leukemic cluster was analyzed by percent contribution of cells by 
patients according to their disease outcome (Table 1). Clusters 5 and 8 were discovered to 
have a higher composition of cells from MRD-negative patients than anticipated, while 
cluster 9 was almost exclusively dominated by cells from MRD-positive patients. A two-
sided Fischer’s exact test revealed that the contingency table indicates a non-independent 
relationship between cluster assignment and disease outcome (p-value < 5e-4).  
The genes defining each leukemic cluster were assessed, and genes with a p-adj 
value less than 0.05 were subjected to PANTHER’s gene ontology (GO) enrichment 
analysis13,14. Cluster 5 was defined by genes associated with DNA replication and 
senescence evasion. Cluster 8 genes were associated with antigen processing and 
presentation via class I MHC and both IFN and TNF signaling pathways. Cluster 9 genes 




A cell cycle phase analysis of the leukemic cells revealed significant association 
with disease outcome (Pearson’s Chi-squared test p-value < 2.2e-16). A higher 
proportion of leukemic cells from MRD-negative patients exhibited gene expression 
characteristic of G2/M- and S-phase when compared to leukemic cells from MRD-
positive patients (Fig. 2).  
Furthermore, analysis of cell-cycle phase assignment according to leukemic 
cluster revealed that cluster 5 is dominated by cells expressing G2M- and S-phase genes, 
corroborating the previous GO finding that this cluster is defined by genes characterized 
by DNA replication and senescence evasion pathways (Fig. 3). 
The number of DEGs according to disease outcome within each of the leukemic 
cell clusters indicate a strong discrepancy in gene expression in clusters 0, 6, and 8 
specifically (Table 2).  
Functional enrichment analysis of the genes upregulated in MRD-negative 
patients’ cells within each leukemic cluster revealed a few molecular trends in these cells. 
Clusters 2, 6, and 8 exhibited increased expression of genes associated with RNA 
binding, with genes in clusters 6 and 8 associating with the respirasome complex. 
Upregulated genes in cluster 0 were implicated in the AP-1 complex and B cell survival 
(JUND, FOS, PIK3R1). Cluster 5 MRD-negative associated genes were connected to 
negative regulation of myeloid cell differentiation (LMO2, NFKBIA, CDK6, FBXW7).  
The most notable trend in pathway enrichment results from the genes upregulated 
in the cells from MRD-positive patients in each leukemic cluster was the recurrence of 
leukocyte activation, which was exhibited in all clusters but 5 and 7. Response to 
cytokine and immune effector process pathways also emerged often, occurring in clusters 
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0, 1, 3, 6 and 8. Additionally, the IgM complex and cell adhesion were correlated with 
clusters 0, 1, 2, 3, 4, and 5. Cluster 6 did not exhibit genes related to the IgM complex, 
but was associated with adhesion and the actin cytoskeleton, and both clusters 6 and 8 
upregulated of various receptor genes. The MRD-positive associated genes of clusters 0, 
6 and 8 also associated these clusters with genes found to be upregulated in 
hematopoietic progenitor cells (HPC) of B lymphocyte lineage CD34+CD45RA+CD10+, 
as found by Haddad et al (2004)15.  
Nonleukemic Cell Population 
The nonleukemic immune cells were assigned to 11 distinct cell types: cells with 
high mitochondrial genes (considered low-quality and omitted in downstream analyses), 
Naïve CD8+ T cells, Naïve CD4+ T cells, nucleated erythrocyte precursors, T regulatory 
cells, memory/effector CD4+ T cells, B cells, memory/effector CD8+ T cells and natural 
killer T cells (unable to be differentiated due to similar gene expression profiles), myeloid 
cells, natural killer T cells, natural killer cells, and hematopoietic stem and progenitor 
cells. These cells are labeled as “High_MT”, “NCD8”, “NCD4”, “Ery”, “Treg”, 
“MCD4”, “B”, “MCD8/NK-T”, “Myeloid”, “NK-T”, “NK” and “HSPC”, respectively, in 
the UMAP plot (Fig. 4). 
Comparing the proportions of each cellular compartment revealed association 
between cell type and disease outcome (Pearson’s Chi-squared test p-value < 2.2e-16). 
The most pronounced contrast is the higher contribution of nucleated erythrocyte 
precursors in the MRD-negative cell compartment when compared to that of the MRD-
positive patients.  
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The immune exhaustion analysis of this cell group revealed a total of 416 cells 
with high exhaustion scores. The majority of these cells were from MRD-positive 
patients (Fig. 5). Pearson's Chi-squared test with Yates' continuity correction revealed 
dependence between exhaustion assignment and disease outcome (p-value < 5.2e-13). 
The number of significant DEGs within each of the peripheral immune cell types 
indicate that some immune cells may vary more according to post-induction disease 
outcome than others (Table 3). The cell types with the greatest number of DEGs are the 
various T cell groups (including the combined MCDB/NK-T compartment and Tregs) 
and the B cells, suggesting that lymphocyte activity may be especially important in 
understanding the immune differences predisposing induction response in pediatric ALL 
patients. 
Each immune cell type exhibited almost identical gene ontology results for the 
genes significantly upregulated in MRD-negative patients. Each cell type (excluding 
erythrocytes) exhibited expression of genes associated with the molecular functions of 
organic acid binding, oxidoreductase activity, heme binding, tetrapyrrole binding and 
transporter activity. Additionally, B cells, the combined MCD8/NK-T cell group, and 
NCD8 cells expressed genes corresponding to lyase activity. In terms of the biological 
processes associated with the genes upregulated in the MRD-negative patients’ immune 
cells, each cell type exhibited genes characteristic of cellular detoxification and antibiotic 
metabolic processes. Each cell type but erythrocytes, naïve T cells and NK cells also 
exhibited genes characterized to be associated with a response to reactive oxygen species.  
While there is a lack of significant GO results for erythrocytes, myeloid cells, 
NCD8 cells, NK cells, NK-T cells and Treg cells within the MRD-positive cellular 
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compartment, patterns emerged among the pathways associated with significantly 
upregulated genes in therapy-unresponsive patients’ other immune cell groups. B cells, 
HSPCs and NCD4 T cells were associated with protein translation processes and the 
ribosome, as well as co-translational protein targeting to the membrane and protein 
localization to the endoplasmic reticulum. In contrast, the significant genes upregulated 
in the MCD4 T cells of MRD-positive patients were linked to regulation of cell migration 
and motility, response to chemokines, and leukocyte homeostasis. Genes upregulated in 
the combined MCD8/NK-T cell group were found to be implicated in defense response, 





Figure 1. Dimensional Reduction Plot of Clustered Leukemic Cells. 
Dimensional reduction of the leukemic cell population using UMAP with cells colored 




Figure 2. Leukemic Cell Cycle Phase Proportions by Outcome.  
Stacked proportion plot showing proportion of cell-phase estimation of leukemic cells 





Figure 3. Leukemic Cell Cycle Phase Proportions by Cluster. 
Stacked proportion plot showing proportion of cell-phase estimation of leukemic cells 




Figure 4. Dimensional Reduction Plot of Peripheral Immune Cells. 
Dimensional reduction of nonleukemic cell population using UMAP with cells colored 




Figure 5. Nonleukemic Dimensional Reduction Plot of Exhausted Cells. 













MRD neg to 
total 
0 807 2344 3151 25.6% 
1 676 2153 2829 31.40% 
2 236 1584 1820 14.90% 
3 247 1181 1428 20.91% 
4 303 1086 1389 27.90% 
5 360 865 1225 41.62% 
6 103 616 719 16.72% 
7 35 176 211 19.89% 
8 53 122 175 43.44% 
9 2 119 121 1.68% 
Total 2822 10246 13068 21.6% 
Leukemic cluster cell contribution by disease outcome. Fischer's two-sided exact test 
resulted in p-value < 5e-4. Cluster 5 and 8 have a notably higher contribution of MRD-




Table 2. Leukemic Cluster DEGs by Outcome. 
Cluster MRD-Neg MRD-Pos 
0 40 78 
1 32 53 
2 38 24 
3 31 59 
4 19 34 
5 27 17 
6 79 86 
7 29 5 
8 79 69 
Table displaying the number of DEGs according to post-induction disease status with 
log2FC> 1 and p-adj< 0.05 within each leukemic cluster. Cluster 9 was not included due 
to its overwhelming composition of MRD-positive patients’ cells. 
 
 
Table 3. Immune Cell Type DEGs by Outcome. 
Cell Type MRD-Neg MRD-Pos 
B 29 27 
Ery 0 4 
HSPC 9 5 
MCD4 14 15 
MCD8/NK-T 29 76 
Myeloid 7 0 
NCD4 17 12 
NCD8 16 11 
NK 4 0 
NK-T 10 0 
Treg 15 14 
Table displaying the number of DEGs according to post-induction disease status with 




As anticipated, both the nonleukemic and leukemic cell populations exhibit 
divergent molecular characteristics according to disease outcome. In the case of the 
leukemic cell population, it was observed that MRD-negative patients’ cells profiled prior 
to therapy are defined by active DNA replication and senescence evasion. Because 
induction therapy functions by targeting rapidly proliferating cells, it is intuitive that 
patients whose malignant cells are undergoing division will respond more effectively to 
this therapeutic approach. MRD-positive patients’ cells, by contrast, are defined by 
leukocyte activation, immune effector processes, and a lower proportion of cells with 
genes attributed to G2M- and S-phases of the cell cycle. This observation is consistent 
with a proportion of cells not being actively dividing and hence able to resist 
chemotherapy and contribute to residual disease. 
Analysis of DEGs within the leukemic cell compartment revealed yet more 
different trends between the malignant cells at diagnosis between patients who would 
then go on to either exhibit a response or resistance to induction. The RNA-binding and 
cellular respiration tendencies of MRD-negative leukemic cells may be due to their 
increased proliferation activity as suggested by the cell cycle assignment analysis. 
Furthermore, the implication of specific AP-1 complex proteins, most notably JUNB and 
FOS, may indicate the prevention of senescence or apoptosis in leukemic cells in MRD-
negative patients16, perhaps also enabling these cells to be effectively targeted by therapy. 
Finally, the association of cluster 5 MRD-negative upregulated genes with negative 
regulation of myeloid cell differentiation corroborates the findings of Witkowski et al that 
myeloid lineage cells may play an essential role in resistant ALL (2020)10. 
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By contrast, the correlation of genes upregulated in MRD-positive leukemic cells 
with pathways rooted in leukocyte activation and immune effector processes may suggest 
that these malignant cells are chronically stimulating nearby effector cells, perhaps 
playing a role in the immune cell exhaustion seen in these patients’ immune cells. The 
repetition of adhesion-related pathways in MRD-positive leukemic cells support the 
findings of Ebinger et al (2016) that implicate this process in resistant leukemia cells7. 
Finally, the relation of the upregulated genes in malignant cells from unresponsive 
patients to genes characteristic of B-lineage HPCs indicates that these cells may exhibit 
stem-cell-like phenotypes, allowing them to evade targeting by induction therapy.  
The peripheral immune cells’ molecular hallmarks also differ according to disease 
outcome. Firstly, the percent contribution of each immune cell type was found to vary 
significantly according to disease outcome, most notably with nucleated erythrocyte 
precursors comprising a much larger fraction of the total cells in MRD-negative patients. 
It was also discovered that more immune cells exhibited genetic profiles characteristic of 
immune exhaustion in MRD-positive patients than the cells of MRD-negative patients, 
further enforcing the idea that immune exhaustion may play a large role in patients’ 
inability to respond to therapy.  
Among the peripheral immune cells, those from MRD-negative patients exhibited 
upregulation of genes involved in detoxification and response to radical oxygen species, 
while the MRD-positive patients’ immune cells exhibited disproportionate expression of 
genes implicated in protein translation processes and, in the case of MCD4 T cells and 
MCD8/NK-T cells, response to signaling molecules and other leukocyte-specific 
processes. These findings suggest that while immune cells of patients sensitive to 
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induction therapy elicit a strong response to the unfavorable conditions imposed by the 
malignant cells in the tumor microenvironment, the majority of immune cells in patients 
with resistant disease instead exhibit the normal cell functioning of protein production.  
It was particularly interesting that various immune cells from MRD-negative 
patients exhibited upregulation of genes involved in heme/tetrapyrrole binding, and 
closer speculation of the specific genes implicated upregulation of at least one 
hemoglobin gene in every lymphoid cell type (HBA1, HBA2, HBB, HBD, HBM). 
Expression of such genes in non-erythroid cells is curious, but Kuo et al (2017) 
previously demonstrated secretion of extracellular vesicles (EV) by erythrocytes, perhaps 
explaining the source of these hemoglobin mRNA transcripts17. In the context of our 
findings, this could indicate that the beta-globin mRNA transcripts detected in the 
peripheral immune cells of MRD-negative patients may be the result of the uptake of EV 
secreted by red blood cells. Furthermore, work done by Danesh et al (2014) implicate that 
erythrocyte-derived EVs may support T-cell survival and proliferation, perhaps 
explaining why we observe an upregulation of HB genes in immune cells coinciding with 
a favorable disease outcome18. 
Overall, the results of this study provide interesting insight into the ways in which 
the bone marrow microenvironment may differ in patients who do versus do not respond 
to therapy. It may be of particular interest to future researchers to further investigate the 
mechanisms by which leukemic cells avoid proliferation, and thereby evade targeting by 
therapy, and the variables underlying whether or not a patient will experience immune 
cell exhaustion. It may also be useful to discern the role played by both leukocyte 
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activation and adhesion mechanisms in resistant leukemic cells, and how these processes 
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